Effect of timing of administration on lipid-lowering efficacy of statins-meta-analysis

被引:0
|
作者
Wang, Chang [1 ]
Quan, Yawen [2 ]
Wang, Linfeng [3 ]
Li, Gang [1 ,4 ]
机构
[1] North China Univ Sci & Technol, Grad Sch, Tangshan, Hebei, Peoples R China
[2] Hebei Med Univ, Grad Sch, Shijiazhuang, Hebei, Peoples R China
[3] Hebei North Univ, Grad Sch, Zhangjiakou, Hebei, Peoples R China
[4] Hebei Gen Hosp, Inst Geriatr Dis, Div Cardiol, Shijiazhuang 050000, Hebei, Peoples R China
基金
中国国家自然科学基金;
关键词
Statins; Low-density lipoprotein cholesterol; Cholesterol; Half-life; Duration of medication; Medication morning and evening; CONTROLLED-RELEASE SIMVASTATIN; OPTICAL COHERENCE TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; SERUM-CHOLESTEROL; EVENING INTAKE; DOUBLE-BLIND; SAFETY; ATORVASTATIN; RATIONALE; THERAPY;
D O I
10.1007/s00228-023-03575-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background To investigate the effect of timing of statin administration on lipid-lowering efficacy.Methods Computer searches of Pubmed, Embase, Cochrane Library, and Web of Science databases from 1986 to 2023. The impact of administration time on the lipid-lowering efficacy of statin drugs was investigated. Following a series of screenings, a funnel plot was constructed to assess its symmetry, and Egger and Beggar tests were conducted using StataMP-64 to evaluate publication bias. Meta-analysis was performed using RevMan 5.3 to combine MD values.Results Fifteen papers (1352 participants) met and included the criteria. The results of the meta-analysis showed that the effect of morning and evening administration time on plasma triglycerides (TG) (P > 0.05) and plasma high-density lipoprotein cholesterol (HDL-C) (P > 0.05) was not statistically significant. There were significant reductions in total cholesterol (TC) (MD: 0.15 mmol/L, 95% CI: 0.06-0.23, P < 0.01) and low-density lipoprotein cholesterol (LDL-C) (MD: 0.10 mmol/L, 95% CI: - 0.00-0.20, P < 0.01) in the night group. According to the analysis results of the half-life of statins, only short half-life statins showed that nocturnal administration reduced LDL-C (MD: 0.21 mmol/L, 95% CI: 0.09-0.33, P < 0.01) and TC (MD: 0.32 mmol/L, 95% CI: 0.18-0.46, P < 0.01) levels and was better than morning administration. Long half-life statins did not show significant differences. In addition, the administration time of short half-life statins also showed that night administration tended to reduce TG (MD: 0.16 mmol/L, 95% CI: 0.02-0.30, P < 0.05) levels. In subgroup analysis according to clinical factors in patients aged < 55 years, there was no significant difference in the timing of administration between the two groups; the efficacy of statins in lowering lipids in patients aged >= 55 years was significantly different in the TC group (P < 0.01) and LDL-C group (P < 0.01). The administration time of the TC group (P < 0.05) and LDL-C group (P < 0.05) in the Americas, Europe, and Asian groups was significantly different for statins. In addition, the American group also showed that the administration time of the two groups was significantly different from the TG group (P < 0.05).Conclusion The efficacy of administering short half-life statin drugs at night in reducing plasma levels of TC, LDL-C, and TG surpasses that of morning administration. However, this study did not determine the impact of timing of statin administration in patients taking long half-life statins on the efficacy of the medication. Therefore, it is recommended to consider patient adherence when. The study was registered on PROSPERO (International Prospective Register of Systematic Reviews) as CRD42022372105 (available at https://www.crd.york.ac.uk/prospero/).
引用
收藏
页码:1641 / 1656
页数:16
相关论文
共 50 条
  • [21] Cardiovascular effects of statins, beyond lipid-lowering properties
    Mihos, Christos G.
    Pineda, Andres M.
    Santana, Orlando
    PHARMACOLOGICAL RESEARCH, 2014, 88 : 12 - 19
  • [22] Beyond lipid-lowering: role of statins in endometrial cancer
    Hafizz, Abdul Muzhill Hannaan Abdul
    Zin, Reena Rahayu Md
    Abd Aziz, Nor Haslinda
    Kampan, Nirmala Chandralega
    Shafiee, Mohamad Nasir
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (10) : 8199 - 8207
  • [23] Beyond lipid-lowering: role of statins in endometrial cancer
    Abdul Muzhill Hannaan Abdul Hafizz
    Reena Rahayu Md Zin
    Nor Haslinda Abd Aziz
    Nirmala Chandralega Kampan
    Mohamad Nasir Shafiee
    Molecular Biology Reports, 2020, 47 : 8199 - 8207
  • [24] Intensive Lipid-Lowering Therapy With Statins for Primary Prevention
    Ishihara, Masaharu
    CIRCULATION JOURNAL, 2012, 76 (01) : 55 - 56
  • [25] Beneficial Effects of Statins on Seizures Independent of Their Lipid-Lowering Effect: A Narrative Review
    Amanlou, Arash
    Nassireslami, Ehsan
    Dehpour, Ahmad Reza
    Rashidian, Amir
    Chamanara, Mohsen
    IRANIAN JOURNAL OF MEDICAL SCIENCES, 2023, 48 (01) : 13 - 25
  • [26] Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events: A meta-analysis
    Dykun, I.
    Mincu, R.
    Totzeck, M.
    Rassaf, T.
    Mahabadi, A. A.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3075 - 3075
  • [27] META ANALYSIS OF LIPID-LOWERING AGENTS FOR PRIMARY NEPHROTIC SYNDROME
    Chen, Haiyan
    Li, Zi
    Ji, Ling
    Yang, Man
    Liu, Guanjian
    Fan, Junming
    NEPHROLOGY, 2005, 10 : A154 - A154
  • [28] Synthetic statins: More data on newer lipid-lowering agents
    Wierzbicki, AS
    CURRENT MEDICAL RESEARCH AND OPINION, 2001, 17 (01) : 74 - 77
  • [29] Lipid-lowering storvastatin - Stroke prevention, a new role for statins?
    不详
    NERVENARZT, 2003, 74 (07): : B1 - B4
  • [30] Beyond lipid-lowering: effects of statins on endothelial nitric oxide
    Ulrich Laufs
    European Journal of Clinical Pharmacology, 2003, 58 : 719 - 731